A5054415027- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Cholinesterase and Neurodegenerative Diseases
- Medical Imaging Techniques and Applications
- Computational Drug Discovery Methods
- Ginkgo biloba and Cashew Applications
- Neurological Disorders and Treatments
- Folate and B Vitamins Research
- Bioinformatics and Genomic Networks
- Neuroinflammation and Neurodegeneration Mechanisms
- S100 Proteins and Annexins
- Educational Games and Gamification
- Genital Health and Disease
- Sleep and Wakefulness Research
- Cannabis and Cannabinoid Research
- Nuclear Receptors and Signaling
- Phosphodiesterase function and regulation
- Kawasaki Disease and Coronary Complications
- Treatment of Major Depression
- Adipokines, Inflammation, and Metabolic Diseases
- Pancreatitis Pathology and Treatment
- Medicinal Plant Extracts Effects
- Mosquito-borne diseases and control
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Vitamin C and Antioxidants Research
Memory Enhancement Center of America
2008-2017
Eaton (United States)
2009-2017
Medical University of South Carolina
2013
Personal Enhancement Center
2013
Ralph H. Johnson VA Medical Center
2013
Stratford University
1998-2000
Ocean Medical Center
1997-2000
Hackensack Meridian Health
1998
In vivo imaging of brain β-amyloid, a hallmark Alzheimer disease, may assist in the clinical assessment suspected disease. To determine sensitivity and specificity positron emission tomography with flutemetamol injection labeled radioactive fluorine 18 to detect β-amyloid using neuropathologically determined neuritic plaque levels as standard truth. Open-label multicenter study that took place at dementia clinics, memory centers, hospice centers United States England from June 22, 2010,...
Abstract Introduction Performance of the amyloid tracer [ 18 F]flutemetamol was evaluated against three pathology standard truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” component 2012 NIA‐AA guidelines). Methods After imaging, 106 end‐of‐life patients who died underwent postmortem brain examination for plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with measures....
Abstract A pilot study, of eight weeks duration, investigated the effects flowering plants upon behavior hospitalized psychiatric patients. The introduction in dining room setting was followed by a significant increase vocalization, time spent room, and amount food consumed. transient, though not statistically number social gazes occured during first week flowers were present.
Amnestic mild cognitive impairment (aMCI) is generally regarded as a prodromal form of AD based on recent studies that found neurofibrillary tangles (NFTs) in the brains aMCI subjects and correlations between NFTs memory loss. Testing drugs target therefore has relevance treatment both AD. Here, we report findings from Phase 2 proof-of-concept clinical trial for with AL-108. AL-108 an intranasal formulation eight amino acid peptide, NAPVSIPQ, derived neuroprotective protein...
Avagacestat, an oral γ-secretase inhibitor that selectively inhibits amyloid-beta (Aβ) synthesis, was investigated in Phase 2 studies to assess safety mild-to-moderate Alzheimer's disease (AD) and predementia AD (PDAD). We report interim data from the first prospective, multicenter, randomized, controlled trial PDAD (CN156–018). CN156–018 assessed safety, tolerability biomarker effects of avagacestat patients with PDAD. Lumbar puncture demonstrating CSF profile consistent pathology required...
The recent failure of semagacestat in two large Phase III studies questions the value γ-secretase inhibitors treating Alzheimer's disease. Understanding reasons this setback may be important for future research on effective treatments devastating
The purpose of this study was to investigate the clinical and caregivers impression Aricept ® treatment in patients suffering from Multi-Infarct Dementia (MID). In a prospective 73 MID patients1 were treated with Donepezil (Aricept®) for 16-to 20-weeks. administered as 5mg tablet once daily at bedtime. After four weeks, tolerant 5-mg dose increased 10 mg daily. All satisfied DSM-III-R criteria Dementia. 2 20-weeks treatment, patient's caregiver completed questionnaire concerning...
CHF5074 is a new microglial modulator that has been shown to prevent brain plaque deposition and attenuate memory deficits in transgenic mouse models of AD. In man, the drug dose-dependently lowers cerebrospinal fluid levels two biomarkers neuroinflammation (sCD40L TNF- a). We monitored safety tolerability cognitive effects after prolonged treatment MCI patients. At end 14-week double-blind, placebo-controlled study 96 patients evaluating three titrated dose regimens (200, 400 600 mg/day),...
The purpose of this study is to investigate the clinical and caregiver impression on Aricept TM treatment. In a prospective study, 57 consecutive Alzheimer's disease patients were treated with Donepezil for 16 weeks, using 5mg tablet, administered once daily at bedtime. Patients met criteria NINCDS-ADRDAI probable disease. There no exclusion study. After 16-weeks treatment, completed questionnaire regarding effectiveness drug. Subjective cognitive improvement, MMSE, 2 ADL, 3 IADL 4 outcomes...
CSF amyloid and tau biomarkers are strong predictors of AD progression from mild cognitive impairment (MCI). Emerging clinical evidence suggests that amyloid-PET imaging has similar utility. The correlation between PET is expected to be high in AD. We performed an exploratory analysis limited baseline data predementia patients (identified by biomarker measurements) enrolled CN156018 who completed florbetapir (florbetapir F 18 [18F-AV-45]) scans examine: 1) concordance pathologic (low Aß42,...
There are currently several anti-amyloid β (Aβ) monoclonal antibodies (mAbs) in clinical development as potential therapeutics to reduce brain amyloid burden and improve outcome patients with Alzheimer's disease (AD). Ponezumab (PF-04360365) is a humanized IgG2deltaA mAb that targets amino acids 33-40 of the Aβ1-40 peptide. Moreover, its constant region (Fc) incorporates two site mutations effector function. The preliminary phase 1 safety pharmacokinetic data for ponezumab following single...
Bapineuzumab, a humanized anti-amyloid-beta (Aβ) peptide monoclonal antibody, is under investigation for the treatment of Alzheimer's Disease (AD). Bapineuzumab hypothesized to reduce Aβ from brain and lead beneficial clinical effect. The pharmacokinetics (PK) pharmacodynamics (PD) bapineuzumab were investigated in Phase IIa randomized, double-blind, placebo-controlled study patients with mild moderate AD. Placebo or at 0.15, 0.5, 1.0, 2.0 mg/kg once every 13 weeks 6 infusions was...
When should I take away the car keys? Is it still safe for him/her to drive? Are all patients diagnosed with Alzheimer's disease (AD) a hazard on road? What about driving short distances in familiar territory? Can people AD drive family or caregiver supervision? Those are but few of difficult questions asked by caregivers AD. There is confusion regarding optimal time recommend that patient stop driving. 1-5 In an attempt assist this question, guidelines have been issued, although they...
CHF5074, a new gamma-secretase modulator, has been shown to inhibit brain plaque deposition and attenuate or reverse associated memory deficits in different human amyloid precursor protein transgenic mice models of Alzheimer's disease (JPET 2007; 323: 822-30, Br J Pharmacol 2009; 156: 982-93; Alzheimers Dis 2010, press). We evaluated for the first time safety, tolerability pharmacokinetics CHF5074 after single oral administration healthy male volunteers. Six ascending doses (25, 50, 100,...
Acetylated Tau is fast becoming one of the earliest recognizable post transcriptionally modified protein in Tauopathies including Alzheimer's Disease. Salsalate, a compound known since times Hippocrates has been shown animal and human AD neuronal cells to significantly improve levels pathological tau (both acetylated phosphorylated as well cognitive/functional performance transgenic mice overexpressing Tau. This ASAP study (Alzheimer's Symptoms Are Preventable) will be first its kind attempt...
CHF5074 has been shown to inhibit brain plaque deposition and attenuate or reverse memory deficits in different transgenic mouse models of AD. In healthy subjects, the drug is well tolerated after multiple doses up 600 mg/day dose-dependently lowers CSF plasma levels soluble CD40 ligand (sCD40L), a biomarker activated microglia. We evaluated safety, tolerability, pharmacokinetics pharmacodynamics 12-week treatment patients with mild cognitive impairment (MCI). Three ascending oral dose...